Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resistance Profile to TL+D in HIV Patients in Brazil
NCT07618507Completed
- Sponsor
- Federal University of São Paulo
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Federal University of São Paulo. Primary endpoint: Prevalence of Transmitted Drug Resistance at 3 months. Started Apr 2022; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07618507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618507.